Hematopoietic Transplantation Leaders Converge in Beijing for Cutting-Edge Academic Exchange

Beijing, April 15, 2019 /PRNewswire/ -- April 13，The Hematopoietic Stem Cell Transplantation Elite Summit Co-hosted by Lu Daopei Hospital and MSDAt the Pullman BeijingSuccessful Convening – This conference is also a significant academic meeting organized by the Hematology Professional Committee of the Chinese Non-Government Medical Institutions Association. The conference co-chairs include Professor Da Wanming, hematologist and Deputy Chairman of the Non-Government Medical Hematology Professional Committee; Professor Zhang Bolong, Deputy Director of the Harbin Institute of Hematology; Professor Zhang Xiaohui, Deputy Director of the Peking University Institute of Hematology; President Lu Peihua of Lu Daopei Hospital; Professor He Pengcheng from the First Affiliated Hospital of Xi’an Jiaotong University; Professor Gao Sujun from the First Hospital of Jilin University; and Professor Wang Zhao from Beijing Friendship Hospital, Capital Medical University.

President Lu Peihua delivered the welcome address: In this vibrant spring month of April, we welcome experts and scholars from 43 hospitals across China to gather together and jointly discuss frontier topics in hematological research. It is our hope that everyone will speak freely and openly, ensuring that all attendees gain valuable insights and enjoy a fulfilling and pleasant weekend in Beijing.

Address by Deputy Director Zhang Xiaohui of the Institute of Hematology, Peking University: Today, experts from various fields of hematology across China have gathered for this grand event. On this occasion, I would like to once again express our respect for Academician Lu Daopei and thank him for his pioneering contributions to the Institute of Hematology at Peking University. Academician Lu’sEarnestHis teachings have greatly benefited the younger generation of hematologists. In recent years, we have been delighted to witness the rapid progress made by Lu Daopei Hospital in areas such as bone marrow transplantation and CAR-T clinical research, with numerous oral presentations and posters from Daopei featured at international academic forums. Moving forward, the Institute of Hematology at Peking University and Lu Daopei Hospital will continue to work hand in hand to jointly advance the development of hematology in China.

Zhang Bolong, Secretary-General of the Hematology Professional Committee of the Chinese Non-Public Medical Institutions Association and Deputy Director of the Harbin Institute of Hematology, introduced the establishment process and recent development overview of the Non-Public Medical Hematology Professional Committee. Under the leadership of Chairman Lu Peihua, all committee members have worked together to carry out a substantial amount of practical and effective work, achieving phased progress in various areas including scientific research, clinical practice, academic lectures and exchanges, and public welfare and charity initiatives related to hematological diseases.

As scheduled, ten experts successively took the stage to deliver academic presentations --

Director Zhang Xian, Department of General Hematology and Immunotherapy, Lu Daopei Hospital: "CAR-T Therapy for Refractory/Relapsed Acute B-Lymphoblastic Leukemia"

She systematically reviewed the clinical application mechanisms, principles, and efficacy of CAR-T cell therapy in clinical trials at Lu Daopei Hospital. This study enrolled patients with various types of ultra-high-risk relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), including those with extramedullary disease (EMD), high tumor burden (HLB), BCR-ABL positive mutations, and post-transplant relapse. Following CD19 CAR-T cell therapy, these patients achieved a very high complete remission rate, with low incidence of adverse effects and manageable cytokine release syndrome (CRS). Furthermore, bridging to allogeneic hematopoietic stem cell transplantation after CAR-T therapy yielded superior long-term outcomes.

Director Lu Yue, Department of Hematopoietic Stem Cell Transplantation, Lu Daopei Hospital: “Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Severe Aplastic Anemia”

Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Acquired Severe Aplastic Anemia (SAA): Alternative donor transplantation, particularly from haploidentical donors (HID), has rapidly developed in China with remarkable efficacy. As either first-line or salvage therapy, HID transplantation achieves outcomes in both children and adults comparable to those with matched sibling donors (MSD) or matched unrelated donors (MUD). Furthermore, we present a comparative study from our institution involving 41 HID cases and 48 concurrent MUD cases for SAA treatment, the results of which indicate that HID yields efficacy similar to MUD (76.4%+ 5.1% vs 89.4% +7.4%, P = .127); however, the incidence of aGVHD was higher in the HID group than in the MUD group, while cGVHD rates were similar between the two groups [Yue Lu, etal.BiolBlood Marrow Transplant, 2018 Sep;24(9):1881-1887]; moreover, recent studies have shown that haploidentical hematopoietic stem cell transplantation (HID-HSCT) as first-line therapy in patients with severe aplastic anemia (SAA), whether children or adults, results in significantly superior disease-free survival compared to concurrent immunosuppressive therapy (IST) as first-line treatment. Therefore, HID-HSCT may be considered as a first-line treatment option for certain SAA patients. Additionally, the Center for International Blood and Marrow Transplant Research (CIBMTR) and the European Society for Blood and Marrow Transplantation (EBMT) recently reported a cohort of patients aged>Transplantation Data in Patients with Severe Aplastic Anemia (SAA) Aged >50 Years (n=499; median age, 57.8 years; 16% aged 65–77 years): Results indicated that patients with a pre-transplant performance status of 90–100% had significantly superior survival rates compared to those with a performance status <90% (94% vs. 72%). Survival rates were not correlated with age, donor type, or graft type. These findings suggest that eligibility for transplantation in elderly SAA patients should be determined by biological age rather than chronological age. For elderly SAA patients with a performance status >90%, transplantation may be considered after failure of immunosuppressive therapy (IST).

Professor Liu Ligen of Tongren Hospital Affiliated to Shanghai Jiao Tong University School of Medicine: “Research Progress in the Diagnosis and Treatment of Refractory and Relapsed Acute Myeloid Leukemia”

Based on international literature and clinical research data, a comparative analysis of the efficacy and toxic side effects of various clinical drugs was conducted, and a prospective exploration of combination drug therapy was performed. For patients with refractory or relapsed acute myeloid leukemia (AML), recommendations for standardized treatment were provided: early precise risk stratification, standardized drug dosing, standardized treatment courses, minimal residual disease (MRD) monitoring, and timely hematopoietic stem cell transplantation.

Professor Miao Miao from the First Affiliated Hospital of Soochow University: "Application of Hematopoietic Stem Cell Transplantation in MDS"

Director Cao Xingyu, Department of Hematopoietic Stem Cell Transplantation, Lu Daopei Hospital: "Diagnosis and Treatment of B-Cell Lymphoblastic Leukemia"

Based on an analysis of international clinical trial results in pediatric and adult B-cell acute lymphoblastic leukemia (B-ALL), this review summarizes advances in the diagnosis and treatment of B-ALL. In terms of diagnosis, identifying high-risk relapse B-ALL at initial presentation, such as Ph-like ALL, is key to further improving long-term prognosis. When diagnosing such cases of B-ALL, emphasis is placed on the importance of precise laboratory testing, including genetic profiling and detection of gene mutations. Regarding treatment, in addition to optimizing the use of conventional chemotherapy agents and adjusting medications based on genetic characteristics and drug metabolism polymorphisms, the incorporation of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive (Ph+) ALL has significantly improved prognosis. Multiple clinical trials are currently underway for the treatment of Ph-like ALL; adding dasatinib or ruxolitinib based on the type of genetic alteration is expected to improve survival rates. Furthermore, bridging hematopoietic stem cell transplantation (HSCT) after CAR-T cell therapy provides an effective treatment pathway for patients with relapsed B-ALL. HSCT results from the Daopei team demonstrate that if minimal residual disease (MRD) negativity is achieved prior to transplantation, the 5-year survival rate exceeds 70%, regardless of whether total body irradiation (TBI) or busulfan (BU)-based conditioning regimens are used, and irrespective of prior CAR-T cell therapy.

Director Wei Zhijie, Department of Hematopoietic Stem Cell Transplantation, Lu Daopei Hospital: "New Advances in Antifungal Prophylaxis for Patients with Hematologic Malignancies and Invasive Fungal Disease"

Patients with hematologic disorders face risk factors for invasive fungal disease (IFD) throughout all stages of treatment, necessitating the selection and application of broad-spectrum, potent, and durable antifungal agents. The antifungal drug posaconazole demonstrates cost-effectiveness in prophylactic therapy for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

Director Zhang Jianping, Department of Hematopoietic Stem Cell Transplantation, Lu Daopei Hospital: "Diagnosis and Treatment of Transplantation-Associated Thrombotic Microangiopathy (TA-TMA)"

"Director Zhou Jiarui of the Hematopoietic Stem Cell Transplantation Department at Lu Daopei Hospital: 'Discussing IFD Prevention Strategies for Allogeneic Hematopoietic Stem Cell Transplant Patients Through Case Studies'"

Discussion on the Necessity and Needs of Invasive Fungal Disease (IFD) Prophylaxis in Hematopoietic Stem Cell Transplantation Patients, and the Advantages of Posaconazole for IFD Prophylaxis: A Case Report of a 65-Year-Old Patient with Acute Myeloid Leukemia Undergoing Haploidentical Salvage Transplantation from Child to Mother

Liu Qiuju, The First Hospital of Jilin University: “Case Discussion – A Case Report of Hepatosplenic Disseminated Candidiasis”

Starting from the epidemiology of invasive fungal disease (IFD) in patients with hematologic disorders, and combining with the treatment process of a patient with acute myeloid leukemia (AML), this study reveals the diagnostic challenges of invasive fungal diseases and discusses stratified diagnosis and targeted therapy for IFD.

Director Sun Ruijuan, Department of Hematopoietic Stem Cell Transplantation, Lu Daopei Hospital: “Case Discussion – Sharing a Case of Refractory Pulmonary Fungal Infection Post-Transplantation”

Analysis of the Management of Pulmonary Complications in a Patient Following Maternal-to-Daughter Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report of a 14-Year-Old with Acute Myeloid Leukemia (M5)

During the morning and afternoon academic sessions, Conference Chair Professor Zhang Xiaohui, President Lu Peihua, and Professor Zhang Bolong, along with Professor He Pengcheng from the First Affiliated Hospital of Xi’an Jiaotong University, Professor Gao Sujun from the First Hospital of Jilin University, and Professor Wang Zhao from Beijing Friendship Hospital, Capital Medical University, successively moderated the Q&A and discussion segments and shared their valuable insights.

In conclusion, Professor Da Wanming, Conference Chair and hematology expert, delivered the closing remarks: “This conference has been a great success. The speakers were well-prepared, covering a wide range of topics with representative case examples. The selected subjects were at the forefront of the field and closely integrated with clinical practice. I believe that, like me, you have all gained substantially from this event. I would like to express my gratitude to all the speakers and attendees for their active participation, and thank Lu Daopei Hospital and MSD for providing this platform, which has enabled numerous experts, scholars, and young talents to learn and exchange ideas together. Such sharing of clinical experience and academic research achievements is particularly meaningful.”